EZH2 and neoplasm: In SCLC-resistant xenograft mouse models, the EZH2 inhibitor EPZ011989 restores tumor sensitivity to irinotecan by upregulating SLFN11, and its combination with irinotecan significantly inhibits tumor growth (90).